CN112638946A - 抗il1rap抗体组合物 - Google Patents

抗il1rap抗体组合物 Download PDF

Info

Publication number
CN112638946A
CN112638946A CN201980054188.9A CN201980054188A CN112638946A CN 112638946 A CN112638946 A CN 112638946A CN 201980054188 A CN201980054188 A CN 201980054188A CN 112638946 A CN112638946 A CN 112638946A
Authority
CN
China
Prior art keywords
seq
sequence identity
amino acid
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980054188.9A
Other languages
English (en)
Chinese (zh)
Inventor
G·福斯伯格
D·利伯格
K·斯约斯特罗姆
K·冯·瓦钦费尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cantargia AB
Original Assignee
Cantargia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cantargia AB filed Critical Cantargia AB
Publication of CN112638946A publication Critical patent/CN112638946A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980054188.9A 2018-08-16 2019-08-15 抗il1rap抗体组合物 Pending CN112638946A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1850983-6 2018-08-16
SE1850983 2018-08-16
PCT/EP2019/071974 WO2020035577A1 (en) 2018-08-16 2019-08-15 Anti-il1rap antibody compositions

Publications (1)

Publication Number Publication Date
CN112638946A true CN112638946A (zh) 2021-04-09

Family

ID=67667857

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980054188.9A Pending CN112638946A (zh) 2018-08-16 2019-08-15 抗il1rap抗体组合物

Country Status (5)

Country Link
US (1) US12209131B2 (https=)
EP (1) EP3837283B1 (https=)
JP (1) JP2022532812A (https=)
CN (1) CN112638946A (https=)
WO (1) WO2020035577A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115353566A (zh) * 2022-09-14 2022-11-18 江苏睿源生物技术有限公司 用于检测白细胞介素1-β的抗体组合及其应用

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12209131B2 (en) 2018-08-16 2025-01-28 Cantargia Ab Anti-IL1RAP antibody compositions
US11970539B2 (en) * 2020-09-14 2024-04-30 Ichnos Sciences SA Antibodies that bind to IL1RAP and uses thereof
JP2024500920A (ja) * 2020-12-23 2024-01-10 カンタージア アクチエボラーグ 抗ｉｌ１ｒａｐ抗体
US20240317868A1 (en) 2021-02-05 2024-09-26 Boehringer Ingelheim International Gmbh Anti-il1rap antibodies
JP2024520338A (ja) * 2021-05-21 2024-05-24 レオ ファーマ アクティーゼルスカブ 抗ｉｌ－１受容体アクセサリータンパク質抗体
CA3226673A1 (en) * 2021-07-21 2023-01-21 Stelexis Therapeutics, Llc Il1rap antibodies and uses thereof
WO2024126833A1 (en) * 2022-12-16 2024-06-20 Ichnos Sciences SA Cd47-il1rap bispecific antibodies
CN116284401B (zh) * 2023-02-20 2024-09-24 中国人民解放军军事科学院军事医学研究院 人源抗il-1r3抗体及其应用
WO2024231251A1 (en) * 2023-05-05 2024-11-14 Cantargia Ab Anti-il1rap antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015132602A1 (en) * 2014-03-05 2015-09-11 Cantargia Ab Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof
WO2016020502A1 (en) * 2014-08-06 2016-02-11 Cantargia Ab Novel antibodies and uses thereof
US20170121420A1 (en) * 2015-11-02 2017-05-04 Janssen Pharmaceutica Nv Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0655924A4 (en) 1992-06-30 1996-09-11 Oncologix Inc A COMBINATION OF MONOCLONAL ANTIBODIES AGAINST erbB-2 AND METHOD FOR THEIR USE.
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US7534866B2 (en) 2005-10-19 2009-05-19 Ibc Pharmaceuticals, Inc. Methods and compositions for generating bioactive assemblies of increased complexity and uses
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7550143B2 (en) 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
EP1874824A4 (en) 2005-04-06 2009-12-30 Ibc Pharmaceuticals Inc METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
JP2010116338A (ja) 2008-11-12 2010-05-27 Evec Inc 同一抗原に特異的に結合する複数の抗体の混合物もしくは複数の抗原結合部位を有する抗体
GB2472856B (en) 2009-08-21 2012-07-11 Cantargia Ab IL1-RAP modulators and uses thereof
RU2597831C2 (ru) 2011-01-19 2016-09-20 Кантаргия Аб Анти-il1rap антитела и их применение при лечении людей
KR102038310B1 (ko) 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
MA43365A (fr) 2015-12-01 2018-10-10 Genmab Bv Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
WO2018071910A2 (en) 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anti-il1-rap antibodies
CA3084459A1 (en) 2016-10-16 2018-04-19 Cellerant Therapeutics, Inc. Anti-il1-rap antibodies
US12209131B2 (en) 2018-08-16 2025-01-28 Cantargia Ab Anti-IL1RAP antibody compositions
JP2024500920A (ja) 2020-12-23 2024-01-10 カンタージア アクチエボラーグ 抗ｉｌ１ｒａｐ抗体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015132602A1 (en) * 2014-03-05 2015-09-11 Cantargia Ab Anti human interleukin-1 receptor accessory protein (il1 rap) antibodies and uses thereof
CN106459195A (zh) * 2014-03-05 2017-02-22 坎塔吉亚有限责任公司 抗人白介素‑1受体辅助蛋白(il1 rap)抗体及其用途
WO2016020502A1 (en) * 2014-08-06 2016-02-11 Cantargia Ab Novel antibodies and uses thereof
US20170121420A1 (en) * 2015-11-02 2017-05-04 Janssen Pharmaceutica Nv Anti-il1rap antibodies, bispecific antigen binding molecules that bind il1rap and cd3, and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HELENA ÅGERSTAM等: "Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia", PNAS, vol. 112, no. 34, 25 August 2015 (2015-08-25), pages 10786 - 10791, XP055308490, DOI: 10.1073/pnas.1422749112 *
尹玲玲等: "抗人ILl RAP单克隆抗体重、轻链基因的克隆及重组嵌合受体的构建", 中国实验血液学杂志, vol. 23, no. 5, 31 December 2015 (2015-12-31), pages 1272 - 1276 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115353566A (zh) * 2022-09-14 2022-11-18 江苏睿源生物技术有限公司 用于检测白细胞介素1-β的抗体组合及其应用
CN115353566B (zh) * 2022-09-14 2023-05-09 江苏睿源生物技术有限公司 用于检测白细胞介素1-β的抗体组合及其应用

Also Published As

Publication number Publication date
EP3837283A1 (en) 2021-06-23
WO2020035577A1 (en) 2020-02-20
EP3837283B1 (en) 2024-04-17
US20220267454A1 (en) 2022-08-25
US12209131B2 (en) 2025-01-28
JP2022532812A (ja) 2022-07-20

Similar Documents

Publication Publication Date Title
US12209131B2 (en) Anti-IL1RAP antibody compositions
TWI853077B (zh) 新型抗ｃｄ３９抗體
US11746148B2 (en) Antibody molecules comprising a single-domain antigen-binding site and Fab fragments
KR101781965B1 (ko) 항-ｉｌ-12/ｉｌ-23 항체
JP6794348B2 (ja) ヒト化抗ｏｘ４０抗体及びその使用
KR20230052910A (ko) Ccr8 항체 및 이의 응용
JP2023503700A (ja) Ｔｓｌｐ関連疾患に対する治療薬の開発及び用途
JP2021526022A (ja) 抗インターロイキン１７ａ抗体、医薬組成物、およびその使用
JP6400480B2 (ja) ペプチドグリカン認識タンパク質１に結合する抗体
WO2017049452A1 (zh) 抗人cd137的完全人抗体及其应用
TW201922784A (zh) ４﹘１ｂｂ抗體及其製備方法和應用
US9670276B2 (en) IL-1 binding proteins
CN112469735B (zh) 用于治疗自发性疾病和癌症的抗cxcl13抗体
KR20240082364A (ko) 인터루킨-2 돌연변이 및 이의 융합 단백질
CN113039208B (zh) 一种抗pd-l1抗原结合蛋白及其应用
CN112969714A (zh) 抗cd40抗体、其抗原结合片段及其医药用途
US20240190983A1 (en) Novel TNFR2 Binding Molecules
JP2023550832A (ja) ＣＤ３９およびＴＧＦβを標的とする新規のコンジュゲート分子
AU2022358565A1 (en) Immunocytokine containing il-21r mutein
CN117062840A (zh) 靶向bcma的多特异性抗体
TW202003854A (zh) 抗人ｌａｇ－３單克隆抗體及其應用
JP7734856B2 (ja) 二重特異性抗体及びその使用
CN121263442A (zh) 抗il1rap抗体
WO2023030511A1 (en) Bi-functional fusion protein and uses thereof
CN121002060A (zh) 犬il-13的犬抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210409

WD01 Invention patent application deemed withdrawn after publication